A pathway to improved prospective observational post-authorization safety studies

Area of Science:

• Pharmacovigilance and Drug Safety
• Clinical Trial Design
• Real-World Evidence

Background:

• Randomized controlled trials (RCTs) are effective for drug efficacy but often lack the power to detect rare or multiple adverse events, limiting their utility in drug safety assessment.
• Post-marketing surveillance and risk management activities are crucial for drug safety, as real-world drug use differs from controlled trial settings.
• Observational studies are increasingly used in post-authorization safety studies (PASS) by regulatory bodies like the European Medicines Agency and the US Food and Drug Administration (FDA) due to their ability to reflect real-world drug utility.

Purpose of the Study:

• To highlight the limitations of RCTs in drug safety assessment.
• To emphasize the growing importance and utility of observational studies in post-authorization safety studies (PASS).
• To identify and discuss the challenges in current prospective observational PASS methodologies and propose improvements.

Main Methods:

• Review of existing literature and practical experience with prospective observational post-authorization safety studies (PASS).
• Analysis of the increasing trend of utilizing observational studies in regulatory post-approval commitments in the US and Europe.
• Identification of recognized inadequacies in current observational PASS methodologies and practices.

Main Results:

• RCTs have inherent limitations in detecting rare or multiple adverse events, making them less suitable for comprehensive drug safety evaluation.
• Observational studies, despite lacking random assignment, offer valuable insights into real-world drug performance and safety.
• There is a notable increase in the adoption of observational studies for post-authorization safety studies (PASS) by major regulatory agencies.

Conclusions:

• Observational studies are essential complements to RCTs for robust drug safety assessment in real-world settings.
• Addressing the methodological inadequacies in observational PASS is critical for enhancing their reliability and impact.
• Further research and development of methodologies for prospective observational PASS are needed to fully leverage their potential in pharmacovigilance.